Colgate-Palmolive (NYSE:CL) Shares Sold by Boston Trust Walden Corp

Boston Trust Walden Corp decreased its position in shares of Colgate-Palmolive (NYSE:CL) by 10.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 198,818 shares of the company’s stock after selling 22,045 shares during the period. Boston Trust Walden Corp’s holdings in Colgate-Palmolive were worth $18,075,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CL. Algert Global LLC raised its stake in shares of Colgate-Palmolive by 14.4% during the second quarter. Algert Global LLC now owns 5,131 shares of the company’s stock worth $498,000 after purchasing an additional 647 shares during the last quarter. Czech National Bank raised its position in Colgate-Palmolive by 6.5% during the 3rd quarter. Czech National Bank now owns 166,449 shares of the company’s stock worth $17,279,000 after buying an additional 10,106 shares during the last quarter. Park Avenue Securities LLC lifted its stake in shares of Colgate-Palmolive by 38.3% in the 3rd quarter. Park Avenue Securities LLC now owns 10,705 shares of the company’s stock worth $1,111,000 after acquiring an additional 2,966 shares during the period. GAMMA Investing LLC increased its stake in shares of Colgate-Palmolive by 32.4% during the third quarter. GAMMA Investing LLC now owns 10,952 shares of the company’s stock worth $1,137,000 after acquiring an additional 2,677 shares during the period. Finally, Miracle Mile Advisors LLC raised its holdings in Colgate-Palmolive by 19.8% during the third quarter. Miracle Mile Advisors LLC now owns 3,842 shares of the company’s stock worth $399,000 after purchasing an additional 636 shares in the last quarter. Hedge funds and other institutional investors own 80.41% of the company’s stock.

Colgate-Palmolive Stock Up 0.4 %

Shares of NYSE:CL opened at $87.05 on Tuesday. Colgate-Palmolive has a 12-month low of $82.68 and a 12-month high of $109.30. The stock’s 50-day moving average price is $91.35 and its two-hundred day moving average price is $97.15. The company has a current ratio of 0.41, a quick ratio of 0.26 and a debt-to-equity ratio of 9.46. The firm has a market cap of $71.12 billion, a price-to-earnings ratio of 24.73, a PEG ratio of 3.61 and a beta of 0.44.

Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings results on Friday, January 31st. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.01. Colgate-Palmolive had a net margin of 14.38% and a return on equity of 477.77%. During the same period last year, the firm posted $0.87 EPS. On average, research analysts forecast that Colgate-Palmolive will post 3.74 EPS for the current year.

Colgate-Palmolive Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Tuesday, January 21st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 2.30%. The ex-dividend date is Tuesday, January 21st. Colgate-Palmolive’s dividend payout ratio is currently 56.82%.

Wall Street Analyst Weigh In

Several research firms have issued reports on CL. Barclays dropped their target price on Colgate-Palmolive from $96.00 to $83.00 and set an “equal weight” rating on the stock in a research report on Friday, January 17th. Stifel Nicolaus dropped their price objective on Colgate-Palmolive from $95.00 to $93.00 and set a “hold” rating on the stock in a report on Monday. Piper Sandler reduced their target price on Colgate-Palmolive from $121.00 to $112.00 and set an “overweight” rating for the company in a report on Monday, January 6th. UBS Group lowered their price target on shares of Colgate-Palmolive from $104.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Wells Fargo & Company decreased their price objective on shares of Colgate-Palmolive from $92.00 to $83.00 and set an “underweight” rating on the stock in a report on Tuesday, January 7th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $101.16.

Colgate-Palmolive Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.